Deputy Chief Medical Officer, Global Oncology Clinical Development

Location: Hong Kong or Guangzhou, China | Full-timeOn-site, with regional and international travel as required.Company and Role OverviewHealth Hope Pharma (HHP) is a late clinical‑stage biopharmaceutical company dedicated to developing innovative therapies in oncology and ophthalmology.

Reporting to the Chief Medical Officer (CMO), the Deputy CMO leads medical and clinical development across HHP’s late-stage portfolio, primarily advancing Phase III global MRCT oncology program.Key Responsibilities· Develop and execute medical and scientific strategy for oncology and other pipeline assets; provide medical leadership for Phase III global multiregional clinical trials (MRCTs).· Build and lead the clinical operations team to oversee the clinical trials of HHP.· Provide medical leadership in collaboration with CROs to address recruitment and clinical execution challenges and support timely, high-quality trial delivery.· Provide medical oversight with investigators and Pharmacovigilance, addressing eligibility, protocol deviations, emerging efficacy and safety findings.· Engage investigators and international key opinion leaders on study design, site readiness, recruitment and delivery.· Lead medical and clinical development discussions with regulatory authorities including but not limited to FDA, NMPA and MHRA, in collaboration with Regulatory Affairs, on development pathways and submissions; ensure compliance with GCP, applicable regulations and HHP quality standards.· Guide data interpretation, benefit–risk assessment and development decisions with Biostatistics and relevant functions.Qualifications and Experience· M.D. or equivalent required; Medical Oncology board certification strongly preferred. PhD, MPH or MBA advantageous.· At least 15 years in pharma/biotech, including 10 years in oncology clinical development.· Essential: leadership of oncology MRCTs in China, including medical oversight and global team coordination; Phase III experience spanning strategy, protocols and data interpretation.· Direct FDA/NMPA engagement with successful oncology outcomes, such as development-plan alignment, submission acceptance or marketing approval.· Ophthalmology development experience advantageous, not required.· Ability to lead cross-functional teams and partners across international markets, including the United States and China, combining strategic leadership with hands-on execution in a growing clinical-stage biotech; strong knowledge of GCP, healthcare compliance, medical governance, trial methodology, patient safety and FDA, NMPA, MHRA and other applicable regulatory requirements.· Professional fluency in English and Chinese to lead scientific discussions with global teams, investigators and regulators.ApplicationSubmit a CV and brief cover letter highlighting global Phase III development, China oncology MRCT leadership, successful FDA/NMPA engagement and, where applicable, ophthalmology experience.HHP is an equal opportunity employer. Employment decisions do not discriminate on grounds of race, colour, religion, sex, sexual orientation, gender identity, national origin, age, disability or other legally protected characteristics. Applicant information is confidential and used solely for recruitment and employment purposes.